NCT00468689View on ClinicalTrials.gov

Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Osteoporosis
Interventions
DRUG

SB-751689 oral tablets (100 and 400 ng)

DRUG

Ketoconazole (NIZORAL) oral tablets (200 mg)

Trial Locations (1)

21225

GSK Investigational Site, Baltimore

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY